EMA Authorised: Feraccru (ferric maltol) — Norgine B.V.

View source ↗

Summary

EMA authorised Feraccru (ferric maltol) for iron-deficiency anemia, with Norgine B.V. as marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• Feraccru (ferric maltol)

Snippet

Status: Authorised. Therapeutic area: Anemia, Iron-Deficiency. MAH: Norgine B.V.. Decision date: 26/05/2026